Sebastien Letard

Marseille, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Telomere occupancy by TRF2 is altered by KIT mutations and correlates with mastocytosis regression.

Telomere occupancy by TRF2 is altered by KIT mutations and correlates with mastocytosis regression.

Journal: Blood cancer journal

Published: May 24, 2025

Dual targeting of CDK6 and LSD1 is synergistic and overcomes differentiation blockade in AML.

Dual targeting of CDK6 and LSD1 is synergistic and overcomes differentiation blockade in AML.

Journal: EMBO molecular medicine

Published: October 18, 2024

The Recurrent Liver MAN2A1-FER Oncoprotein Lacks Kinase Activity: Implications for the Use of Tyrosine Kinase Inhibitors.

The Recurrent Liver MAN2A1-FER Oncoprotein Lacks Kinase Activity: Implications for the Use of Tyrosine Kinase Inhibitors.

Journal: Cellular and molecular gastroenterology and hepatology

Published: December 04, 2023

TET2 regulates immune tolerance in chronically activated mast cells.

TET2 regulates immune tolerance in chronically activated mast cells.

Journal: JCI insight

Published: August 17, 2021

Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.

Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.

Journal: British journal of haematology

Published: April 16, 2019

Dual protein kinase and nucleoside kinase modulators for rationally designed polypharmacology.

Dual protein kinase and nucleoside kinase modulators for rationally designed polypharmacology.

Journal: Nature communications

Published: February 01, 2017

Familial hematological malignancies: new IDH2 mutation.

Familial hematological malignancies: new IDH2 mutation.

Journal: Annals of hematology

Published: August 21, 2016

Dual Role of the Tyrosine Kinase Syk in Regulation of Toll-Like Receptor Signaling in Plasmacytoid Dendritic Cells.

Dual Role of the Tyrosine Kinase Syk in Regulation of Toll-Like Receptor Signaling in Plasmacytoid Dendritic Cells.

Journal: PloS one

Published: November 12, 2015

Screening of candidate G-quadruplex ligands for the human c-KIT promotorial region and their effects in multiple in-vitro models.

Screening of candidate G-quadruplex ligands for the human c-KIT promotorial region and their effects in multiple in-vitro models.

Journal: Oncotarget

Published: September 14, 2015

Activation of KIT modulates the function of tumor necrosis factor-related apoptosis-inducing ligand receptor (TRAIL-R) in mast cells.

Activation of KIT modulates the function of tumor necrosis factor-related apoptosis-inducing ligand receptor (TRAIL-R) in mast cells.

Journal: Allergy

Published: March 18, 2015

In aggressive forms of mastocytosis, TET2 loss cooperates with c-KITD816V to transform mast cells.

In aggressive forms of mastocytosis, TET2 loss cooperates with c-KITD816V to transform mast cells.

Journal: Blood

Published: October 18, 2012

Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor.

Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor.

Journal: European journal of haematology

Published: February 14, 2012

Showing 1-12 of 13

Last Updated: 09/26/2026